References
- Jain A, Nalesnik M, Reyes J, Pokharna R, Mazariegos G, Green M, et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg 2002;236:429-36. https://doi.org/10.1097/00000658-200210000-00005
- Lai YC, Ni YH, Jou ST, Ho MC, Wu JF, Chen HL, et al. Post-transplantation lymphoproliferative disorders localizing to the gastrointestinal tract after liver transplantation: report of five pediatric cases. Pediatr Transplant 2006;10:390-4. https://doi.org/10.1111/j.1399-3046.2005.00457.x
- Leblond V, Choquet S. Lymphoproliferative disorders after liver transplantation. J Hepatol 2004;40:728-35. https://doi.org/10.1016/j.jhep.2004.03.006
- 기현균, 손경목, 위유미, 이지영, 문치숙, 오원섭 등. 간이식 후 발생한 림프구 증식성 질환의 임상적 양상. 감염과 화학요법 2006;38:131-9.
- 최연호, 이석구, 서정민, 조재원, 김성주, 이광웅 등. 소아 간이식에서 Posttransplant lymphoproliferative disorder(PTLD): 삼성서울병원의 경험. 대한소아소화기영양학회지 2003;6:39-46.
- Aucejo F, Rofaiel G, Miller C. Who is at risk for post-transplant lymphoproliferative disorders (PTLD) after liver transplantation- J Hepatol 2006;44:19-23. https://doi.org/10.1016/j.jhep.2005.10.008
- Duvoux C, Pageaux GP, Vanlemmens C, Roudot- Thoraval F, Vincens-Rolland AL, Hezode C, et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation 2002;74:1103-9. https://doi.org/10.1097/00007890-200210270-00008
- Green M, Webber S. Posttransplantation lymphoproliferative disorders. Pediatr Clin North Am 2003;50:1471-91. https://doi.org/10.1016/S0031-3955(03)00127-5
- Guthery SL, Heubi JE, Bucuvalas JC, Gross TG, Ryckman FC, Alonso MH, et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation 2003;75:987-93.
- Kremers WK, Devarbhavi HC, Wiesner RH, Krom RA, Macon WR, Habermann TM. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant 2006;6:1017-24. https://doi.org/10.1111/j.1600-6143.2006.01294.x
- Bakker NA, van Imhoff GW, Verschuuren EA, van Son WJ. Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation. Transpl Int 2007;20:207-18. https://doi.org/10.1111/j.1432-2277.2006.00416.x
- Wu JF, Ho MC, Ni YH, Chen HL, Lu CY, Hsu HY, et al. Timing of Epstein-Barr virs acquisition and the course of posttransplantation lymphoproliferative disorder in children. Transplantation 2009;87:758-62. https://doi.org/10.1097/TP.0b013e318198d645
- Spada M, Guizzetti M, Petz W, Colledan M, Segalin A, Lucianetti A, et al. Circulating EBV-DNA in the monitoring of EBV infection in pediatric liver transplant recipients. Transplant Proc 2001;33:1835-7. https://doi.org/10.1016/S0041-1345(00)02828-1
- Scheenstra R, Verschuuren EA, de Haan A, Slooff MJ, The TH, Bijleveld CM, et al. The value of prospective monitoring of Epstein-Barr virus DNA in blood samples of pediatric liver transplant recipients. Transpl Infect Dis 2004;6:15-22. https://doi.org/10.1111/j.1399-3062.2004.00044.x
- Toyoda M, Moudgil A, Warady BA, Puliyanda DP, Jordan SC. Clinical significance of peripheral blood Epstein-Barr viral load monitoring using polymerase chain reaction in renal transplant recipients. Pediatr Transplant 2008:12:778-84. https://doi.org/10.1111/j.1399-3046.2008.00904.x
- Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004;103:3979-81. https://doi.org/10.1182/blood-2003-12-4287
- Wagner HJ, Wessel M, Jabs W, Smets F, Fischer L, Offner G, et al. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using realtime quantitative polymerase chain reaction. Transplantation 2001;72:1012-9. https://doi.org/10.1097/00007890-200109270-00006
- Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005;5:2222-8. https://doi.org/10.1111/j.1600-6143.2005.01002.x
- Rowe DT, Webber S, Schauer EM, Reyes J, Green M. Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis 2001;3:79-87. https://doi.org/10.1034/j.1399-3062.2001.003002079.x
- Axelrod DA, Holmes R, Thomas SE, Magee JC. Limitations of EBV-PCR monitoring to detect EBV associated post-transplant lymphoproliferative disorder. Pediatr Transplant 2003;7:223-7. https://doi.org/10.1034/j.1399-3046.2003.00080.x
- O'Connor JA, Cogley C, Burton M, Lancaster-Weiss K, Cordle RA. Posttransplantation lymphoproliferative disorder: endoscopic findings. J Pediatr Gastroenterol Nutr 2000;31:458-61. https://doi.org/10.1097/00005176-200010000-00026
- Younes BS, Ament ME, McDiarmid SV, Martin MG, Vargas JH. The involvement of the gastrointestinal tract in posttransplant lymphoproliferative disease in pediatric liver transplantation. J Pediatr Gastroenterol Nutr 1999;28:380-5. https://doi.org/10.1097/00005176-199904000-00007
- Gershman G, Vargas J, Ament ME. The role of endoscopy in diagnosis of lymphoproliferative disorder in the gastrointestinal tract of children after liver transplantation. J Pediatr Gastroenterol Nutr 1998;26:575.
- Tsao L, Hsi ED. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med 2007;131:1209-18.
- Dharnidharka VR, Araya CE. Post-transplant lymphoproliferative disease. Pediatr Nephrol 2009;24:731-6. https://doi.org/10.1007/s00467-007-0582-3
- Frey NV, Tsai DE. The management of posttransplant lymphoproliferative disorder. Med Oncol 2007;24:125-36. https://doi.org/10.1007/BF02698031
- McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998;66:1604-11. https://doi.org/10.1097/00007890-199812270-00006
- Faller DV, Mentzer SJ, Perrine SP. Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol 2001;13:360-7. https://doi.org/10.1097/00001622-200109000-00008
- Koch DG, Christiansen L, Lazarchick J, Stuart R, Willner IR, Reuben A. Posttransplantation lymphoproliferative disorder - the great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus. Liver Transpl 2007;13:904-12. https://doi.org/10.1002/lt.21152
- Choquet S, Leblond V, Herbrecht R, Socié G, Stoppa AM, Vandenberghe P, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006;107:3053-7. https://doi.org/10.1182/blood-2005-01-0377
- Svoboda J, Kotloff R, Tsai DE. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab. Transpl Int 2006;19:259-69. https://doi.org/10.1111/j.1432-2277.2006.00284.x
- Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23:1088-95. https://doi.org/10.1200/JCO.2005.12.191
- Smets F, Sokal EM. Lymphoproliferation in children after liver transplantation. J Pediatr Gastroenterol Nutr 2002;34:499-505. https://doi.org/10.1097/00005176-200205000-00004
- Lim WH, Russ GR, Coates PT. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation. Nephrology 2006;11:355-66. https://doi.org/10.1111/j.1440-1797.2006.00596.x